MedTrace Logo

Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone

NCT04392037 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-03-28

No results posted yet for this study

Summary

Evaluation of the effect iberdomide combined with low-dose cyclophosphamide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Conditions

Interventions

DRUG

Iberdomide plus low-dose cyclophosphamide and dexamethasone

Iberdomide, low dose Cyclophosphamide and Dexamethason will be given until progression or unacceptable toxicity

Sponsors & Collaborators

  • Celgene

    collaborator INDUSTRY

  • Amsterdam UMC, location VUmc

    lead OTHER

Principal Investigators

  • N.W.C.J van de Donk, Prof. MD PhD · Amsterdam UMC, location VUmc

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-17
Primary Completion
2027-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04392037 on ClinicalTrials.gov